CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Go back to CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)| (NASDAQ: CRVO) | Delayed: 2.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.86 | 52 Week High | $ | |||
| Open | $2.86 | 52 Week Low | $ | |||
| Day High | $2.86 | P/E | N/A | |||
| Day Low | $2.86 | EPS | $ | |||
| Volume | 2,630 | |||||
